NewsTrending topic
Can a Gaucher Disease Pill Kill Cancer Cells? What the Study Found
A viral post says an FDA-approved pill, eliglustat, makes cancer cells die. It did, in lab dishes. No animal or human cancer testing yet, and it is not a treatment.
Original commentary from the Cancer Explained editorial team.
Review status: AI-assisted. Not reviewed by a clinician. How we check pages
Sources last checked .
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
“Experts just discovered that an FDA-approved pill jams the recycling system cancer cells depend on — and they die.”
Nothing has loaded from Instagram. We do not connect you to Meta unless you ask, because that would let them set cookies through this page. Open it on Instagram instead.
"Experts just discovered that an FDA-approved pill jams the recycling system cancer cells depend on — and they die."
That is how an Instagram post from @hashem.alghaili, shared around November 11, 2026, begins. The drug is eliglustat, sold as Cerdelga. The study is real, and the post's longer caption is careful. But the first line is the one most people read, so here is what the research did and did not show.
What eliglustat is
Eliglustat is approved in the United States for adults with Gaucher disease type 1, a rare inherited condition in which a fatty substance builds up in the body. It works by blocking an enzyme called glucosylceramide synthase (GCS). It is not approved to treat any cancer.
What the study did
The study was published in Cell Death Discovery in August 2026 by a team at VCU Massey Comprehensive Cancer Center in Virginia. The first author is Alexandra Straus, and the senior author is Can Senkal.
The team treated several cancer cell lines with eliglustat and with other drugs that block the same enzyme. They also turned the enzyme off genetically. According to the university's announcement, the cells came from colon, ovarian and cervical cancers. In each case, the cancer cells died.
They then looked for the cause. For years, researchers thought blocking this enzyme hurt cancer cells by letting a fat called ceramide build up. This study found something else. The cells' lysosomes, small sacs that break down worn-out parts so they can be reused, swelled up and stopped working. When the team used another compound to restart lysosome activity, the cells survived.
What it did not show
- It was done in lab dishes. Neither the paper's summary nor the announcement describes animal or human cancer testing.
- Lab doses may not match safe doses. Drugs often kill cells in a dish at levels people cannot safely take. The post's own caption makes this point.
- It is not a treatment. No trial has tested eliglustat as a cancer treatment on its own.
There is a real reason for interest, though. Because eliglustat is already approved for another disease, its safety in people is better known than a brand-new compound's. The university says the findings may matter for ongoing clinical trials that combine eliglustat with immunotherapy. Steps like these, from lab to animals to people, are explained in our page on clinical trial phases.
The verdict
Accurate about the lab study, but early. The drug killed cancer cells in dishes, by breaking their recycling system. It has not been shown to treat cancer in people.
If you have cancer
Do not try to get eliglustat on your own. It is a prescription drug for a different disease, and it can interact with many other medicines. If you are interested in new approaches, ask your care team about clinical trials that might fit you.
For help judging headlines like this one, see how to evaluate cancer news.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
The information below is general, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
A news story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.